Placeholder Banner

BIO Submits Comments on FDA Draft Guidance on Expedited Programs for Regenerative Medicine Therapies for Serious Conditions

February 15, 2018

BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, Expedited Programs for Regenerative Medicine Therapies for Serious Conditions.

This draft guidance provides important information on the expedited programs available to sponsors of regenerative medicine therapies for serious conditions. BIO recommends the FDA provide further guidance to sponsors on which designation (RMAT or Breakthrough Therapy) is most appropriate for different types of programs, along with other comments on how to clarify the guidance.

 

Download Full Comments Below
BIO Letter Expedited Programs For Regenerative Medicine Therapies Draft Guidance FINAL 2-15-18
Read full comment letter below
Discover More
The Biotechnology Innovation Organization (BIO) is pleased to respond to the U.S. Department of Agriculture’s (USDA) Solicitation of Input from Stakeholders on Agricultural Innovations. BIO applauds USDA for taking a proactive approach and seeking…
July 31, 2020 Re: Docket No. FDA–2020-N-0837: Raare Disease Clinical Trial Network; Request for Information. Dear Sir/Madam: The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA or Agency) for the…
July 30, 2020 Re: Docket No. FDA–2019-D-5799: FDA’s Public Meeting, Modernizing the Food and Drug Administration’s Data Strategy. Dear Sir/Madam: The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA or…